Predictive biomarkers in muscle-invasive bladder cancer

Predictive biomarkers in muscle-invasive bladder cancer

<p>Organ-confined muscle-invasive bladder cancer (MIBC) is treated with either radical cystectomy (RC) or radiotherapy (RT) and carries survival rates of only 40-60%. There is no clear survival advantage between the two therapies and therefore biomarkers that could aid in the choice of treatme...

Bibliografiset tiedot
Päätekijä:	Walker, A
Muut tekijät:	Kiltie, A
Aineistotyyppi:	Opinnäyte
Julkaistu:	2017

Samankaltaisia teoksia

Utility of bladder-sparing therapy vs radical cystectomy for muscle-invasive bladder cancer
Tekijä: Efstathiou, J, et al.
Julkaistu: (2018)

MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer
Tekijä: Teo, M, et al.
Julkaistu: (2012)

THE HYPOXIC REGULATION OF FGFR3 IN NON MUSCLE INVASIVE BLADDER CANCER
Tekijä: Blick, C, et al.
Julkaistu: (2011)

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
Tekijä: Zuiverloon, TCM, et al.
Julkaistu: (2018)

Contemporary patterns of multidisciplinary care in patients with muscle-invasive bladder cancer
Tekijä: Harshman, LC, et al.
Julkaistu: (2017)

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
Tekijä: Hermans, TJN, et al.
Julkaistu: (2017)

Predictive Biomarkers for Gemcitabine as a Chemoradiosensitizer in Bladder Cancer
Tekijä: Kerr, M, et al.
Julkaistu: (2012)

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
Tekijä: Choudhury, A, et al.
Julkaistu: (2010)

The management of non-muscle-invasive bladder cancer: A comparison of European and UK guidelines
Tekijä: Leiblich, A, et al.
Julkaistu: (2018)

Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Tekijä: Choudhury, A, et al.
Julkaistu: (2011)

MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer
Tekijä: Walker, AK, et al.
Julkaistu: (2019)

Mouse models of muscle-invasive bladder cancer: Key considerations for clinical translation based on molecular subtypes
Tekijä: Ruan, J, et al.
Julkaistu: (2018)

Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer
Tekijä: Leiblich, A
Julkaistu: (2017)

High MRE11 expression in muscle invasive bladder cancer is predictive of improved cause-specific survival following radical radiotherapy compared to surgery
Tekijä: Teo, T, et al.
Julkaistu: (2010)

PemBla: a Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer
Tekijä: Woodcock, VK, et al.
Julkaistu: (2023)

Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Tekijä: Ali-El-Dein, B, et al.
Julkaistu: (2013)

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628]
Tekijä: National Institute for Health and Care Excellence, CA, et al.
Julkaistu: (2018)

Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG638]
Tekijä: National Institute for Health and Care Excellence, CA, et al.
Julkaistu: (2019)

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Tekijä: Fujiyama, C, et al.
Julkaistu: (2001)

A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer
Tekijä: Choudhury, A, et al.
Julkaistu: (2010)

Evaluation of OTX1 as a potential biomarker of bladder cancer
Tekijä: Baharudin, Aminuddin
Julkaistu: (2018)

Improving gene array analysis: The application of artificial intelligence identifies novel biomarkers of non invasive papillary bladder cancer progression
Tekijä: Wild, P, et al.
Julkaistu: (2007)

High-throughput DNA sequencing identifies novel CtIP (RBBP8) variants in muscle-invasive bladder cancer patients
Tekijä: Jevons, S, et al.
Julkaistu: (2015)

Ultrasound mediated gemcitabine delivery reduces the normal tissue toxicity of chemoradiation therapy in a muscle-invasive bladder cancer model
Tekijä: Ruan, J-L, et al.
Julkaistu: (2021)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
Tekijä: Kiltie, A, et al.
Julkaistu: (2018)

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer
Tekijä: Kiltie, A, et al.
Julkaistu: (2018)

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
Tekijä: Teo, M, et al.
Julkaistu: (2014)

Artificial intelligence for the prediction bladder cancer
Tekijä: Abbod, M, et al.
Julkaistu: (2004)

Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.
Tekijä: Jones, A, et al.
Julkaistu: (2002)

Overexpression of CTAG1B is a potential biomarker in bladder cancer
Tekijä: Mansor, Siti Farizan, et al.
Julkaistu: (2014)

Evaluation of CERS2 gene as a potential biomarker for bladder cancer
Tekijä: Aldoghachi, Ahmed Faris, et al.
Julkaistu: (2019)

An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer
Tekijä: Ord, J, et al.
Julkaistu: (2007)

An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer.
Tekijä: Ord, J, et al.
Julkaistu: (2007)

Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer
Tekijä: Smittenaar, P, et al.
Julkaistu: (2018)

Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
Tekijä: Crew, J, et al.
Julkaistu: (2000)

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential
Tekijä: Derré, L, et al.
Julkaistu: (2023)

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder
Tekijä: Blick, C, et al.
Julkaistu: (2012)

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Tekijä: Blick, C, et al.
Julkaistu: (2012)

Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer
Tekijä: Blick, C, et al.
Julkaistu: (2013)

Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.
Tekijä: Blick, C, et al.
Julkaistu: (2013)